Is there hope for HER2-positive colorectal cancer with Trastuzumab? A review of current evidence.
Gbolahan Olatunji, Nicholas Aderinto, Emmanuel Kokori, Michael Awoyinfa, Oluwafemi Ajimotokan, Joan Oluwadamilola Ajayi, Nitin Narayan Rao, Ajayi Oluwatomisin Temidayo, Tejiri Napoleon, Chimezirim Ezeano, Sulaimon Olaide Bukky, Emmanuel Elorm Nortey-Adom, Sharon Aa-Inir Karbo, Israel Charles Abraham
Abstract
Open AccessTrastuzumab combinations are emerging as a promising therapeutic strategy for HER2-positive colorectal cancer. This review investigates the current clinical data on efficacy and safety. Clinical trials have shown encouraging results, with objective response rates (ORRs) ranging from 22.2 to 46% and complete remission achievable in some patients. Additionally, these combinations demonstrate potential for improved overall survival (OS). However, optimizing therapeutic strategies remains crucial. Future research should tailor treatment regimens based on tumor biology and individual patient characteristics. Investigating ctDNA genotyping as a reliable method for identifying responders and exploring the role of Rat Sarcoma Virus (RAS) mutations and other molecular markers are key areas for optimizing patient selection and treatment efficacy. Understanding resistance mechanisms is vital for developing combination therapies that overcome these pathways.